Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(9):643; doi:10.1093/jnci/djj167
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cuzick, J.
Right arrow Articles by Howell, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuzick, J.
Right arrow Articles by Howell, A.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

CORRESPONDENCE

Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Jack Cuzick, John F. Forbes, Anthony Howell

Affiliations of authors: Wolfson Institute of Preventive Medicine, University of London, London, United Kingdom (JC); Mater Hospital, University of Newcastle, Newcastle, Australia (JFF); Christie Hospital, Manchester, United Kingdom (AH)

Correspondence to: Jack Cuzick, PhD, Wolfson Institute of Preventive Medicine, University of London, Charterhouse Square, London, EC1M 6BQ, UK (e-mail: jack.cuzick@cancer.org.uk).

The first 10% of the full text of this article appears below.

We read with great interest the recent report of Fisher et al. (1) on the longer-term follow up of the P-1 trial. This article underlines the importance of determining the effect of tamoxifen prophylaxis in the 5-year period following treatment. Unfortunately, interpretation of the data for P-1 is very . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher and Joseph P. Costantino
J Natl Cancer Inst 2006 98: 643-644. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
J. Cuzick, J. F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell
Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial
J Natl Cancer Inst, February 21, 2007; 99(4): 272 - 282.
[Abstract] [Full Text] [PDF]